



NDA 22122/S-017

SUPPLEMENT APPROVAL

GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
Attention: Rita D. Patel, RAC
Regulatory Affairs Senior Manager
184 Liberty Corner Rd, Suite 200
Warren, NJ 07059

Dear Ms. Patel:

Please refer to your supplemental new drug application (sNDA) dated and received January 21, 2021, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Voltaren Arthritis Pain (diclofenac sodium) topical gel, 1%.

This Changes Being Effected sNDA provides the following changes in support of a new 120 g packaging configuration: 1) New 120 g (b) (4) tubes with blue Osteo Arthritis (OA) cap with corresponding labeling and 2) Update the (b) (4) hold time of product as (b) (4)

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

LABELING

Submit final printed labeling (FPL), as soon as they are available, but no more than 30 days after they are printed. The FPL must be identical to the enclosed labeling, described in the table below, and must be in the “Drug Facts” format (21 CFR 201.66), where applicable.

Draft Submitted Labeling	Date Submitted
Voltaren Arthritis Pain Topical Gel; 120g outer container (carton)	January 21, 2021
Voltaren Arthritis Pain Topical Gel; 120g immediate container (tube)	January 21, 2021

The FPL should be submitted electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*.¹ For administrative purposes, designate this submission “**Final Printed Labeling for approved NDA 22122/S-017.**” Approval of this submission by FDA is not required before the labeling is used.

DRUG REGISTRATION AND LISTING

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at FDA.gov.² Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

¹ We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

² <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

If you have any questions, call LCDR Sally Doan, Regulatory Project Manager, at (301) 796-8025.

Sincerely,

{See appended electronic signature page}

Nushin Todd, MD, PhD
Director (Acting)
Division of Nonprescription Drugs I
Office of Nonprescription Drugs
Office of New Drugs
Center for Drug Evaluation and Research

ENCLOSURE:

- Carton and Container Labeling

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

NUSHIN F TODD
07/19/2021 03:34:46 PM